Polyphenon E, non-futile at neuroprotection in multiple sclerosis but unpredictably hepatotoxic: Phase I single group and phase II randomized placebo-controlled studies

Journal of the Neurological Sciences

Volumn 358, Issue 1-2, 2015, Pages 46-52

  Lovera, Jesus ^a   Ramos, Alexander ^a   Devier, Deidre ^a   Garrison, Virginia ^b   Kovner, Blake ^a   Reza, Tara ^a   Koop, Dennis ^d   Rooney, William ^d   Foundas, Anne ^e   Bourdette, Dennis ^c  

^a LOUISIANA STATE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b Department of Behavioural Science   (United States)

^c OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

^d OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

^e UNIVERSITY OF MISSOURI KANSAS CITY SCHOOL OF MEDICINE   (United States)

Author keywords

EGCG; Green tea; Hepatotoxicity; Liver toxicity; Magnetic resonance spectroscopy; Multiple sclerosis; N acetyl aspartate; Polyphenon E

Indexed keywords

CATECHIN; EPIGALLOCATECHIN GALLATE; NEUROPROTECTIVE AGENT; PLANT EXTRACT; POLYPHENON E;

ADULT; ANALOGS AND DERIVATIVES; CLINICAL TRIAL; CONTROLLED STUDY; ENZYMOLOGY; FEMALE; HUMAN; MALE; MIDDLE AGED; MULTIPLE SCLEROSIS; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; RANDOMIZED CONTROLLED TRIAL; TOXIC HEPATITIS; TREATMENT OUTCOME;

ADULT; CATECHIN; CHEMICAL AND DRUG INDUCED LIVER INJURY; FEMALE; HUMANS; MALE; MIDDLE AGED; MULTIPLE SCLEROSIS; NEUROPROTECTIVE AGENTS; PLANT EXTRACTS; TREATMENT OUTCOME;

EID: 85027921191     PISSN: 0022510X     EISSN: 18785883     Source Type: Journal    
DOI: 10.1016/j.jns.2015.08.006     Document Type: Article

References (22)

1. Schroeder, E.K., Kelsey, N.A., Doyle, J., Breed, E., Bouchard, R.J., Loucks, F.A., et al. Green tea epigallocatechin 3-gallate accumulates in mitochondria and displays a selective antiapoptotic effect against inducers of mitochondrial oxidative stress in neurons. Antioxid. Redox Signal. 11:3 (2009), 469–480, 10.1089/ARS.2008.2215.
2. Nikic, I., Merkler, D., Sorbara, C., Brinkoetter, M., Kreutzfeldt, M., Bareyre, F.M., et al. A reversible form of axon damage in experimental autoimmune encephalomyelitis and multiple sclerosis. Nat. Med. 17:4 (2011), 495–499, 10.1038/nm.2324.
3. Aktas, O., Prozorovski, T., Smorodchenko, A., Savaskan, N.E., Lauster, R., Kloetzel, P.M., et al. Green tea epigallocatechin-3-gallate mediates T cellular NF-kappa B inhibition and exerts neuroprotection in autoimmune encephalomyelitis. J. Immunol. 173:9 (2004), 5794–5800 (DOI:173/9/5794 [pii]).
4. Herges, K., Millward, J.M., Hentschel, N., Infante-Duarte, C., Aktas, O., Zipp, F., Neuroprotective effect of combination therapy of glatiramer acetate and epigallocatechin-3-gallate in neuroinflammation. PLoS One, 6(10), 2011, e25456, 10.1371/journal.pone.0025456.
5. Moffett, J.R., Namboodiri, M.A., Cangro, C.B., Neale, J.H., Immunohistochemical localization of N-acetylaspartate in rat brain. Neuroreport 2:3 (1991), 131–134.
6. Moffett, J.R., Ross, B., Arun, P., Madhavarao, C.N., Namboodiri, A.M., N-Acetylaspartate in the CNS: from neurodiagnostics to neurobiology. Prog. Neurobiol. 81:2 (2007), 89–131, 10.1016/j.pneurobio.2006.12.003.
7. Urenjak, J., Williams, S.R., Gadian, D.G., Noble, M., Specific expression of N-acetylaspartate in neurons, oligodendrocyte-type-2 astrocyte progenitors, and immature oligodendrocytes in vitro. J. Neurochem. 59:1 (1992), 55–61.
8. Bjartmar, C., Battistuta, J., Terada, N., Dupree, E., Trapp, B.D., N-acetylaspartate is an axon-specific marker of mature white matter in vivo: a biochemical and immunohistochemical study on the rat optic nerve. Ann. Neurol. 51:1 (2002), 51–58.
9. Krauspe, B.M., Dreher, W., Beyer, C., Baumgartner, W., Denecke, B., Janssen, K., et al. Short-term cuprizone feeding verifies N-acetylaspartate quantification as a marker of neurodegeneration. J. Mol. Neurosci. 55:3 (2015), 733–748, 10.1007/s12031-014-0412-6.
10. Ciccarelli, O., Toosy, A.T., De Stefano, N., Wheeler-Kingshott, C.A., Miller, D.H., Thompson, A.J., Assessing neuronal metabolism in vivo by modeling imaging measures. J. Neurosci. 30:45 (2010), 15030–15033, 10.1523/JNEUROSCI.3330-10.2010 (DOI:30/45/15030 [pii]).
11. Khan, O., Shen, Y., Caon, C., Bao, F., Ching, W., Reznar, M., et al. Axonal metabolic recovery and potential neuroprotective effect of glatiramer acetate in relapsing-remitting multiple sclerosis. Mult. Scler. 11:6 (2005), 646–651.
12. Polman, C.H., Reingold, S.C., Edan, G., Filippi, M., Hartung, H.P., Kappos, L., et al. Diagnostic criteria for multiple sclerosis: 2005 revisions to the “McDonald Criteria”. Ann. Neurol. 58:6 (2005), 840–846.
13. Lublin, F.D., Reingold, S.C., Defining the clinical course of multiple sclerosis: results of an international survey. National Multiple Sclerosis Society (USA) Advisory Committee on Clinical Trials of New Agents in Multiple Sclerosis. Neurology 46:4 (1996), 907–911.
14. Kurtzke, J.F., Rating neurologic impairment in multiple sclerosis: an expanded disability status scale (EDSS). Neurology 33:11 (1983), 1444–1452.
15. Chow, H.H., Cai, Y., Hakim, I.A., Crowell, J.A., Shahi, F., Brooks, C.A., et al. Pharmacokinetics and safety of green tea polyphenols after multiple-dose administration of epigallocatechin gallate and polyphenon E in healthy individuals. Clin. Cancer Res. 9:9 (2003), 3312–3319.
16. Chow, H.H., Hakim, I.A., Vining, D.R., Crowell, J.A., Ranger-Moore, J., Chew, W.M., et al. Effects of dosing condition on the oral bioavailability of green tea catechins after single-dose administration of Polyphenon E in healthy individuals. Clin. Cancer Res. 11:12 (2005), 4627–4633, 10.1158/1078-0432.CCR-04-2549 (DOI:11/12/4627 [pii]).
17. Kapetanovic, I.M., Crowell, J.A., Krishnaraj, R., Zakharov, A., Lindeblad, M., Lyubimov, A., Exposure and toxicity of green tea polyphenols in fasted and non-fasted dogs. Toxicology 260:1-3 (2009), 28–36, 10.1016/j.tox.2009.03.007.
18. Masukawa, Y., Matsui, Y., Shimizu, N., Kondou, N., Endou, H., Kuzukawa, M., et al. Determination of green tea catechins in human plasma using liquid chromatography-electrospray ionization mass spectrometry. J. Chromatogr. B Analyt. Technol. Biomed. Life Sci. 834:1-2 (2006), 26–34, 10.1016/j.jchromb.2006.02.008 (DOI:S1570-0232(06)00102-4 [pii]).
19. Smith, S.M., Zhang, Y., Jenkinson, M., Chen, J., Matthews, P.M., Federico, A., et al. Accurate, robust, and automated longitudinal and cross-sectional brain change analysis. NeuroImage 17:1 (2002), 479–489 (DOI:S1053811902910402 [pii]).
20. Shanafelt, T.D., Call, T.G., Zent, C.S., LaPlant, B., Bowen, D.A., Roos, M., et al. Phase I trial of daily oral Polyphenon E in patients with asymptomatic Rai stage 0 to II chronic lymphocytic leukemia. J. Clin. Oncol. 27:23 (2009), 3808–3814, 10.1200/JCO.2008.21.1284.
21. Shanafelt, T.D., Call, T.G., Zent, C.S., Leis, J.F., LaPlant, B., Bowen, D.A., et al. Phase 2 trial of daily, oral Polyphenon E in patients with asymptomatic, Rai stage 0 to II chronic lymphocytic leukemia. Cancer 119:2 (2013), 363–370, 10.1002/cncr.27719.
22. Crew, K.D., Brown, P., Greenlee, H., Bevers, T.B., Arun, B., Hudis, C., et al. Phase IB randomized, double-blinded, placebo-controlled, dose escalation study of polyphenon E in women with hormone receptor-negative breast cancer. Cancer Prev. Res. 5:9 (2012), 1144–1154, 10.1158/1940-6207.CAPR-12-0117.